Showing posts with label gynecologic cancer. Show all posts
Showing posts with label gynecologic cancer. Show all posts

Friday, May 22, 2026

Looking Forward to #ASCO26

This year's ASCO Annual Meeting runs from May 29 - June 2, 2026 in Chicago. The theme this year is "The Science and Practice of Translation:Improving Cancer Outcomes Worldwide". 

I will be attending virtually, so I know I will experience FOMO when I see the postings by other cancer advocates on social media. I will not miss the long walks to get to sessions in the various buildings at McCormick. But I will miss meeting up with other cancer advocates in the ASCO Advocate Lounge and interacting with gyn cancer researchers who through the years have become friends. 

There are a few new ASCO Voices that I look forward to following this year on X including @DrBarbiOnc, @NazliDizman ,  @Ramila, @YGaritaonaindia  and @DrSAHAddad. I recommend you follow them too, 

I recently planned my attendance to focus on ovarian cancer session. 

Friday May 29  

Gyn Cancer Oral Abstracts 3:45-4:45 (ET)  Livestream 

Sat May 30 

Gyn Cancer Rapid Oral abstract Session 9am (ET)

Opening Session  Livestream 

ctDNA in Clinical Practice 9am Livestream

Rare Gyn Cancers 5:45 

Antibody Drug Conjugates 5:45 Livestream 

Sun May 31 

Let's Debate: Upfront Surgery Versus Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

State of the Art: Therapeutic Strategies on the Horizon for Gynecologic Malignancies

Monday June 1 

New Horizons for Hereditary Cancer Syndromes  

Gyn Cancer Poster session  ( posters available day of session) 

 

I'm ready to listen and learn. 

If you are attending in person please use the #gyncsm hashtag in your social media posts. I'll be posting highlights from the meeting following ASCO. 

 

Dee Sparacio

Every Day is a Blessing! 


 

 

 

Friday, June 7, 2024

Gyn Cancer Poster Session - Ovarian Cancer posters #ASCO24

Monday was Gyn Cancer Poster day at #ASCO24.  

Here are a few posters along with their study conclusions that I found most interesting this year. 

Tumor-informed ctDNA as an objective marker for postoperative residual disease in epithelial ovarian cancer. #5544
"The present tumor-informed dPCR SV fingerprint ctDNA approach demonstrated feasibility with remarkably high detection rates pre- and postoperatively. Postoperative ctDNA levels differed substantially based on postoperative tumor residuals. These findings suggest that this personalized approach could be used to develop a dPCR SV detection assay and may have clinical utility for postoperative MRD evaluation in patients with primary advanced HGSOC."  
Through the years there has been a lot of talk regarding detecting circulating tumor DNA in the blood of patients. This study showed ctDNA could be used  as a marker in ovarian cancer .


Differences in physical and emotional distress amongst patients undergoing neoadjuvant chemotherapy versus surgery for advanced ovarian cancer: Patient-reported outcomes at diagnosis.   #5546
"Advanced OC patients have high psychosocial needs, with NACT patients reporting severe perceived symptoms on PRO measures. The PSS-10 may be a valuable screening tool for patients undergoing NACT to prioritize supportive care services."

Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer. #5547
This work "demonstrated the reliability of using cfDNA from ascites for molecular profiling, allowing a liquid biopsy of ovarian cancer when tumor tissue access may be restricted. This approach improves accessibility of tumour material, allowing capture of clinically actionable mutations prior to surgery or upon recurrence, following tumour evolution."
There is a difference between cfDNA and ctDNA- "The ctDNA is the fraction of cfDNA that originates from tumor cells, which comes from three sources: apoptosis, necrosis, and active secretion. While ctDNA can come from apoptosis with fragment lengths similar to healthy patients, ctDNA is more fragmented or shorter than cfDNA [20,32,33]. "  Source : NIH

Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. #5548
"Cisplatin in combination with gemcitabine demonstrates activity regardless of platinum sensitivity status in patients with recurrent ovarian cancer. However, longer platinum-free interval is associated with improved response to this therapy".

 Evaluation of a novel extracellular vesicle (EV) based ovarian cancer (OC) screening test in asymptomatic postmenopausal women. #5553
"The OC Test is capable of highly sensitive and specific detection of HGSC in asymptomatic postmenopausal women one year prior to Dx and can detect HGSC up to three years prior to Dx with superior sensitivity and specificity compared to CA125." 
Finding a screening test for ovarian cancer is important.  This is a different approach looking at extracellular vesicles. " Extracellular vesicles (EVs) are generated and released by cells as part of various physiological and pathological processes, including the progression of ovarian cancer. "Source Science Direct
 

The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings? #5563
"This real world study provides support for findings from ICON7 and GOG-0218, suggesting that the benefit of adding bev to first line chemotherapy may be limited to patients with high-risk clinical factors ( Stage IV disease or stage III disease with visible residual disease or no evidence of surgery). "

 
Association of physical activity with self-reported quality of life after primary chemotherapy for ovarian cancer. #5574
"We observed positive associations between health tracker physical activity data and pt-reported QOL. Stronger associations were observed in younger pts. Interventions aimed at increasing physical activity may have broader quality of life benefits for individuals with ovarian cancer." 
When I was first diagnosed I was told to rest during chemotherapy treatment. When I recurred a few years later I was told to try to walk each day. I'm glad that theren is now data saying that exercise has QOL benefits.

 
Artificial intelligence to predict homologous recombination deficiency in ovarian cancer from whole-slide histopathological images. #5578
"By harnessing the power of deep neural networks (DNN), we provide a rapid and scalable solution for HRD prediction, circumventing the limitations of traditional molecular assays. Successful integration of this deep learning model into routine pathology workflows could significantly enhance diagnostic efficiency, reduce the turnaround time and financial cost compared with molecular assay. " 
There were a number of talks at ASCO related to the use of AI. HRD is a marker used to manage ovarian cancer patient treatments.

 
Germline genetic profiles of women with ovarian malignancies: A Myriad Collaborative Research Registry study #5585
"Based on this large registry, our data showed that over 15% of patients with ovarian malignancies have mutations in BRCA (12.5%) or Lynch genes (2.6%) with varying prevalence by race, age, and tumor site. Noted disparities indicate the importance of universal testing in patients with epithelial ovarian malignancies."  
I knew that Lynch syndrome was associated with endometrial cancer but I did not associate ovarian cancer with Lynch sydrome. 

 
Which posters caught your eye? Share them in a comment below.
Tomorrow,  I will post about a equity symposium I attended as well as the  connections and reconnections I made at the annual meeting.
Dee
Every Day is a Blessing!

Thursday, June 6, 2024

Sunday at #ASCO24 Oral Abstracts and Rare Gyn Cancers

My meeting days all started with picking up a bite to eat in the Patient Lounge. The lounge was a great place to meet up with other advocates from around the world, relax is comfy chairs  and pick up a bite to eat at breakfast or lunch. 

Sunday started with the Gyn Cancer Oral Abstract Session followed by an afternoon of meeting with clinicians I am working with as well as learning about Patient Story .

Clear Cell OC

 Recurrent OC no additional benefits from adding Atezolizumab

 Endometrial Cancer 

Pharma support of trials 

When Bad News Comes Through the Portal ... Education Session

Exploring the Uncommon: What's New in Rare Gyn Cancers  - Low grade serous , Melanoma of the gyn tract and neuroendocrine carcinomas of the cervix

Obesity and Endometrial Cancer

Cervical Cancer

Metastatic disease clinical trials 

 Tomorrow I'll review a few of the posters as well as a round-up of the connections I made. 


Dee

Every Day is a Blessing!

Friday, May 19, 2023

Prepping for ASCO 2023

The  ASCO Annual meeting begins two weeks from today! This year I will attend virtually. I'll miss interacting with so many amazing researchers and getting to network with some outstanding advocates in the Advocate Lounge. 

You will catch me tweeting from the Live sessions and retweeting attendee's tweets for those sessions which are On Demand. Once the On Demand sessions are over they will become available for me to watch online so I can tweet or summarize them on this blog.  

Be sure to follow #gyncsm, #ASCO23 and ASCO Featured Voices, to be announced shortly by ASCO.

Since I am registered, I was able to set up an agenda using the Annual Meeting Program Guide https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide.

 Here is my schedule so far: 

Friday 

 
Saturday 

 

Sunday

Monday 


 

There are also some sessions that are not specifically about gynecologic cancer that I've added to my agenda. 

On Demand session Improving Cancer Outcomes by Addressing Social Determinants of Health

On Demand Developing Sustainable Cancer and Aging Programs

On Demand Poster Discussion -Prevention, Reduction and Hereditary Cancer

There are a number of published abstracts/ articles in the ASCO 2023 Educational Book, which you can view at https://ascopubs.org/toc/edbk/current . You might want to check out  (e10035)  Patient Advocates and Researchers as Partners in Cancer Research: A Winning Combination if you are an advocate or researcher wanting to engage advocates in your research.

Be sure to check back during and after the meeting for blog posts on the topics / sessions I mentioned above. 

Are you an advocate who is presenting or on a panel? Let me know so I can be sure to watch. 

Dee 

Every Day is a Blessing! 


Thursday, April 30, 2020

A Guest Post: A Gyn Onc's Thoughts on Cancer Care in the Time of COVID-19


Over that past few weeks I have read many articles and heard patients describe their feelings of having to deal with a cancer diagnosis and treatment in the time of COVID-19. A few days ago I read an article in Reuters about how medical testing and cancer screenings have dropped since the outbreak.  
I am pleased to share this guest post by Mira Hellmann MD, Gynecologic Oncologist, Regional Cancer Care Associates, Hackensack University Medical Center on Cancer Care in the Time of COVID-19. 



The WHO (World Health Organization) declared the Coronavirus  outbreak a pandemic on 3/11/2020. This led to immediate action around the world aimed at decreasing the spread of infection.Many different recommendations have emerged regarding safety and precautions that are necessary in order to slow the spread of the pandemic and to save as many lives as possible. Furthermore, fears of collapsing the healthcare systems resulted in recommendations that reserved much of the system’s resources for management of patients diagnosed with COVID-19. Various cancer societies around the world put together suggested guidelines regarding the care and management of cancer patients during this pandemic. These recommendations were derived from data from China that indicated a significantly higher risk of coronavirus in patients with active cancer, and potentially in patients with a history of cancer. In some reports cancer was noted to be present in up to 20% of coronavirus infected patients. Mortality also appeared to be higher in active cancer patients, with a mortality rate of 2.3% in the overall population versus 5.6% in the active cancer patient population. These recommendations resulted in a precipitous drop in patient visits to the doctor. For patients who do present for treatment, modifications to standard treatments were recommended, such as withholding surgical or chemotherapy interventions in slower growing cancers, and modifying management in more aggressive cancers including increasing use of outpatient therapies and non cytotoxic therapies in lieu of surgery or cytotoxic chemotherapy.
This started six weeks ago. We have now learned more about the disease, its pattern of spread, and most importantly its anticipated trajectory. As more data emerges the likelihood of this pandemic ending abruptly; and thereby resulting in a rapid reopening of all services and resumption of normal standard of care,  is rapidly decreasing. As time progresses, the concern for rising rates of adverse non COVID outcomes, such as cancer, become more acute. Some have dubbed this the distraction effect. The extent of this effect is currently unmeasured, but with further delay in care the magnitude of this effect will continue to grow. According to the American Cancer Society 5,000 new cancer cases are diagnosed daily in the US. Given the current restrictions with access to health care, many of these cancers are going undiagnosed. Many cancers, including ovarian cancer and high grade endometrial cancer, as well as other solid and liquid tumors,  are time sensitive in terms of  treatment urgency and its effects on cancer outcomes. According to a report published in Reuters 4/28/2020 rates of screening tests for various cancers, including cervical cancer,  have plummeted in the United States since mid March, with a notable drop of 68% nationally, and even higher in coronavirus hotspots. Since we have gained more insight into the disease, we have managed to institute measures that increase safety of delivery of care, at the same time avoiding compromising the quality of the care. Universal masking measures, both for patients as well as providers, symptoms screening, including screening of contacts, and more readily available swab testing, amongst many other measures, have dramatically improved the safety of delivery of care. Telehealth, although useful in some situations, lacks physical exam, which is integral  to evaluating gynecologic malignancies.  I am urging all patients to be proactive about their cancer care, and ensure that they are not having their cancer care compromised.  Please go to your doctor, or find a doctor who will see you. Please do not allow fear to interfere with your health care. 

Stay healthy, stay safe.

Mira Hellmann MD
Gynecologic Oncologist, Regional Cancer Care Associates, Hackensack University Medical Center


Thank you Dr Hellmann. 

Dee Sparacio
Every Day is a Blessing!

Monday, March 12, 2018

New Research : Biopsychosocial Distress Associated with Breast and Gynecologic Cancer

Last week I read this tweet.
After tweeting questions about the study to  Dr Bergerot, she kindly shared with me the complete article.

Here are some details from the study.

This study was a retrospective quantitative study part of a larger study which took place at City of Hope. It used the City of Hope electronic screening device called You , Your Family and City of Hope are a Team that measures distress.The screening tool involved over 30 core questions and also asked participants their preferred method of assistance/support ( None, Written Info, Talk, Talk + Written Info).

There were 2111 breast cancer patients and 641 gynecologic cancer patients who took part in the study . Most gyn patients were late stage and older (M 57.17 yrs) than the breast cancer patients. There was no significant difference in their body mass.

The study found that gyn cancer patients reported higher problem-related distress compared to breast cancer patients in the following areas:
  • fatigue
  • pain
  • walking or climbing stairs
  • bowel movement/ constipation
  • questions and fear of end of life
  • feeling angry and irritable 
  • needing practical help at home

Gyn cancer patients requested to Talk with a team member about the following issues at a higher level than breast cancer patients:
  • understanding treatment options
  • solving problems
  • fear of medical procedures

Gyn patients also requested Written Information and Talk for at a higher level than breast cancer patients:
  • side effects of treatments
  • finances
  • pain
  • fatigue
  • feeling anxious or fearful


The researchers found that having a gyn cancer and being diagnosed at a younger age were significant predictors of total distress.

In conclusion researchers found that gyn cancer patients had higher problem-related distress. They found no significant difference between cervical and ovarian cancers on the sum of  biopsychosocial problems, which shows they are both at high risk for distress.

It was also found that gyn cancer patients requested to talk to a member of their team more often than breast cancer patients. The authors stated that preexisting support for breast cancer patients may be the reason for lower requests from breast cancer patients.

While the study hypothesized that gyn cancer patients would represent a high-risk group for high levels of distress they did not expect that gyn cancer patients would required higher levels of assistance.  The article stated, "the computerized touch screen system may have facilitated the expression of needs and concerns despite cancer stigma: In research involving sensitive or embarrassing information, electronic questionnaires have been more accepted by patients and more sensi- tive than paper questionnaires." Age , race, education and annual income could also contribute to problem-related distress.

Source:
Bergerot CD, Clark KL, Obenchain R, Philip EJ, Loscalzo M. Breast and gynecological cancer patients' risk factors associated with biopsychosocial problemrelated distress. PsychoOncology. 2018;27:10131020. https://doi.org/10.1002/pon.4607
 
 
In my 13 years as an ovarian cancer survivor I have seen some improvement in support of gyn cancer patients. There are more in-person gynecologic cancer support and networking groups, gynecologic cancer awareness organizations providing platforms online for peer support and more attention being given to gyn cancers symptoms during Gyn Cancer Awareness Month ( September).

But this study verifies that we need to understand that the needs of gyn cancer patients may be different and require different support than other women's cancers. 

Dee
Every Day is a Blessing! 





Sunday, March 12, 2017

#Trials4GynCancerNow - An SGO Campaign to Increas Gyn Cancer Clinical Trials

I wrote this blog post for the #gyncsm blog.  But I thought this topic is so important I needed to share it with my readers and others who may not be on Twitter. 

The SGO (Society of Gynecologic Oncology) is conducting their Annual Meeting March 12-15, 2017. You can follow research presented at the meeting by following the hashtag #SGOMtg on Twitter. Note that we'll discuss SGO Meeting highlights during our April 12th #gyncsm chat

During their annual meeting, SGO will be conducting a social media campaign to advocate for gynecologic cancer clinical trials. #gynscm is please to support this campaign and we hope you will join us.

There has been a steep decline in the number of clinical trials in gynecologic cancer since the restructuring of the NCI-sponsored cooperative groups in 2012.  Information about the campaign can be found in this SGO document.

You can join us as #gyncsm supports this campaign by tweeting the following starting on Monday, March 13th at 9:35am EST:
Women with #gyncancer deserve progress. Fund trials now @realDonaldTrump #Trials4GynCancerNow @SGO_org

Feel free to send additional tweets using #Trials4GynCancerNow to encourage increased funding of NCI trials. 

Thanks, 


Dee Every Day is a Blessing

Wednesday, June 8, 2016

The Days of ASCO 2016

I returned yesterday from the ASCO Annual Meeting in Chicago.  Over 30,000 oncologists, researchers, related professionals and advocates attended the meeting. McCormick Place was very busy from June 3 -7 , 2016. And the amount of information on topics from tumor biology to immunotherapy to targeted therapy to care delivery to the value of care was at times overwhelming.

In Chicago Here I Come- ASCO 2016, I wrote about the sessions I had hoped to attend. But it turns out even after planning a schedule in advance I still had to make adjustments. I didn't attend the Patient and Survivor Care, the Cancer Prevention and Epidemiology or the Genomics and Biomarker sessions. But I did add the Developmental Therapeutics and Transitional Research session on Biosimilars and the ASCO Book Club session When Breathe Becomes Air  as wells as a special advocate session on TAPUR to my schedule.

Some more schedule adjustments were made when I learned I would have the privilege of hearing Vice President Biden address the meeting attendees.  It was a great experience  and an ASCO experience I will not forget. Hearing him talk about the Cancer Moonshot program and how important collaboration and big data is to program gave me hope that it will a success.


Over the next week or so I will blog about the sessions I attended in person. I plan to cover:
  • Ovarian Cancer Research: IV vs IP chemotherapy, neoadjuvant chemotherapy and immunotherapy/targeted therapy study results
  • Endometrial and Cervical Cancer studies
  • Liquid Biopsies in Precision Medicine
  • Biosimilars in Cancer Treatment
  • ASCO's TAPUR Study 
In addition to the research I heard about, there are other benefits of attending the ASCO meeting. I was able to ask questions, share my story and thank the researchers and oncologists who have made finding a cure for cancer their priority. In the Advocate Lounge and at the Research Advocacy Network dinner and the President's reception,  I was able to interact with other research advocates. We talked about how we could be better advocates, how we could work together to make a difference and how we could reach more survivors through social media. Those interactions will have a separate blog post.

I look forward to sharing what I learned with my readers. 

Dee
Every Day is a Blessing


Wednesday, September 30, 2015

My Women of Teal

Over the past ten years I have met many women diagnosed with ovarian cancer as well as other gynecologic cancers. Some of these women I interacted with in real life - at events, support groups and through ovarian cancer awareness organizations.  Other women I got to know through online groups - Facebook, Inspire or Smart Patients. On this the last day of Gynecologic Cancer Awareness month I write this post to honor those diagnosed as well as to remember the women whose lives were lost to a gynecologic cancer. These women have touched my life. 

In Memory of Women of Teal
Jeanne Burton -NJ, endometrial
Linda Juarez - NJ
Joanie Triestain
Heidi Rogol- NJ
Stella Bentivenga- NJ
Colette Fitzpatrick- UK
Shari R. Widmayer - NJ
Kimberly MacDonald- DE
Teresa Whittle - UK
Grace Rocha - NJ
Erika Rocha - NJ
Dietlind Mayer Lawrence- Michigan
Deirdre Berry, NJ
Maggie - KS
Karen Koop Gregorovic- NJ
Carolie Byng- UK
Laurel Phillips- Texas
Pam Favocci- Wall, NJ
Rita Kay Thomas- Piscataway, NJ
Mary Jean Tonkovich- NJ
Shirley Harris - NJ, Endometrial
Ann Bugdal -NJ,  Endometrial
Nicole Christison- NJ
Mary Ellen Csehi - NJ, Endometrial
Monica Orloff- NJ
Jeanne Moran - NJ
Jo McGowran - UK
Gaynor Hall- UK
Sarah Feather
Patty Higgins
Janet Rigdon
Jayne Armstrong- CA
Ellen Santaniello- NJ
Courtney Clifford- Ohio
Denise Carter- NJ
Mary Slattery- NJ
Lisa Niebert- NJ
Fran- NJ
Lyn Rossi- NJ
Diane Waller, Michigan
Gail McNeil- NJ
Sharon Morris- NJ
Cindy Owens- Va
Ann Hall- NJ


In Honor of Survivors of Gynecological Cancer

Terry 
Tina
Susan
Theresa
Betsy
Emmie
Audrey
Theresa
Patricia
Carole F
Lois M
Maria C
Karen
Sandy
Sandhy
Victoria
Emily
MaryAnne
Kia
Rachel
Tracey
Claire
Stacy
Natalie
Rebecca
Alicia
Emily
Patricia
Susan

...too many lives impacted by this disease.

Dee
Every Day is a Blessing!